Information fra kliniske undersøgelser I to kliniske undersøgelser med komplicerede hud - og bløddelsinfektioner opfyldte 36% af patienterne behandlet med Cubicin kriteriet for systemisk inflammatorisk responssyndrom (SIRS).
Information from clinical trials In two clinical trials in complicated skin and soft tissues infections, 36% of patients treated with Cubicin met the criteria for systemic inflammatory response syndrome (SIRS).